Top tier pharma will see lacklustre growth after tough 2012
This article was originally published in Scrip
Executive Summary
Top tier companies are expected to see a 2% decline in total sales in 2012 before posting lacklustre growth through to 2017, according to a half-year update report from Datamonitor which extrapolates ahead from companies' most recently reported results (Half Year 2012: Big pharma update). Key patent expiries of best selling drug and concomitant increases in generic competition will, the report says, prompt a $5.7 billion decline in the total 2012 sales of the leading 12 pharma companies at $390.5 billion. By 2017, aggregate sales at the top tier companies are forecast to be back to $392.7 billion.